JP2002544172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002544172A5 JP2002544172A5 JP2000616818A JP2000616818A JP2002544172A5 JP 2002544172 A5 JP2002544172 A5 JP 2002544172A5 JP 2000616818 A JP2000616818 A JP 2000616818A JP 2000616818 A JP2000616818 A JP 2000616818A JP 2002544172 A5 JP2002544172 A5 JP 2002544172A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- polypeptide
- antibody
- composition according
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 239000003814 drug Substances 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 102000003390 tumor necrosis factor Human genes 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 229940039227 diagnostic agent Drugs 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- IDINUJSAMVOPCM-UHFFFAOYSA-N 15-Deoxyspergualin Natural products NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- BLUYEPLOXLPVCJ-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxyethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC[C@H](O)NC(=O)CCCCCCNC(N)=N BLUYEPLOXLPVCJ-INIZCTEOSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13292299P | 1999-05-06 | 1999-05-06 | |
| US60/132,922 | 1999-05-06 | ||
| PCT/US2000/012163 WO2000067793A1 (en) | 1999-05-06 | 2000-05-05 | Death domain containing receptor 4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002544172A JP2002544172A (ja) | 2002-12-24 |
| JP2002544172A5 true JP2002544172A5 (https=) | 2007-10-25 |
Family
ID=22456184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000616818A Pending JP2002544172A (ja) | 1999-05-06 | 2000-05-05 | 死ドメイン含有レセプター４ |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1178828A4 (https=) |
| JP (1) | JP2002544172A (https=) |
| AU (1) | AU4984300A (https=) |
| CA (1) | CA2373063A1 (https=) |
| WO (1) | WO2000067793A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6455040B1 (en) | 1997-01-14 | 2002-09-24 | Human Genome Sciences, Inc. | Tumor necrosis factor receptor 5 |
| US8329179B2 (en) | 1997-01-28 | 2012-12-11 | Human Genome Sciences, Inc. | Death domain containing receptor 4 antibodies and methods |
| US6342363B1 (en) | 1997-01-28 | 2002-01-29 | Human Genome Sciences, Inc. | Death domain containing receptor 4 nucleic acids and methods |
| US7476383B2 (en) | 2000-05-02 | 2009-01-13 | The Uab Research Foundation | Antibody selective for DR4 and uses thereof |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| AU2002256895B2 (en) * | 2001-05-18 | 2008-09-18 | Kirin Beer Kabushiki Kaisha | Anti-TRAIL-R antibodies |
| MXPA03010747A (es) | 2001-05-25 | 2004-03-02 | Human Genome Sciences Inc | Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral. |
| WO2003013584A1 (en) * | 2001-08-09 | 2003-02-20 | Genset S.A. | Xafinix agonists and antagonists for use in the treatment of metabolic disorders |
| ES2357225T3 (es) * | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
| WO2006067210A1 (en) * | 2004-12-23 | 2006-06-29 | Laboratoires Serono S.A. | Bcma polypeptides and uses thereof |
| KR101292961B1 (ko) | 2005-02-02 | 2013-08-02 | 더 유에이비 리서치 파운데이션 | 아폽토시스-유도 사멸 수용체 작용제에 대한 내성을 감소시키는데 관련된 약제 및 방법 |
| ES2812208T3 (es) | 2013-03-14 | 2021-03-16 | Bristol Myers Squibb Co | Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US6342363B1 (en) * | 1997-01-28 | 2002-01-29 | Human Genome Sciences, Inc. | Death domain containing receptor 4 nucleic acids and methods |
| AU8400398A (en) * | 1997-07-11 | 1999-02-08 | Trustees Of The University Of Pennsylvania, The | Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use |
| AU2338299A (en) * | 1998-01-26 | 1999-08-09 | Genentech Inc. | Antibodies to death receptor 4 (dr4) and uses thereof |
-
2000
- 2000-05-05 AU AU49843/00A patent/AU4984300A/en not_active Abandoned
- 2000-05-05 CA CA002373063A patent/CA2373063A1/en not_active Abandoned
- 2000-05-05 JP JP2000616818A patent/JP2002544172A/ja active Pending
- 2000-05-05 EP EP00932061A patent/EP1178828A4/en not_active Withdrawn
- 2000-05-05 WO PCT/US2000/012163 patent/WO2000067793A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002543151A5 (https=) | ||
| JP4764627B2 (ja) | 新生物疾患又は免疫不全を処置するためのヒト化免疫調節性モノクローナル抗体 | |
| US8470991B2 (en) | Immunocytokine sequences and uses thereof | |
| ES2305110T3 (es) | Anticuerpos contra la il-1 beta humana. | |
| JP4716350B2 (ja) | 潜伏期膜タンパク質に対する抗体およびそれらの使用 | |
| EP0633931B1 (en) | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon | |
| JP3360108B2 (ja) | 二つのエフェクター機能を有する二元特異性異種抗体 | |
| JP2002544172A5 (https=) | ||
| JP2006505244A5 (https=) | ||
| WO2011137687A1 (zh) | 一种抗癌胚抗原抗体及其应用 | |
| EP1159003B1 (en) | Anti-tnf alpha antibodies in therapy of steroid resistant asthma | |
| EP1706423A2 (en) | Therapeutic and diagnostic anti-hsp 70 antibodies | |
| CA2240834C (en) | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines | |
| US20070202102A1 (en) | High-Yield Method For The Production Of Human Antibodies Blocking The Biological Activity Of A Human Cytokine | |
| Nishimoto et al. | 2-3). Anticytokine therapy in autoimmune diseases | |
| US20080138275A1 (en) | Hybridoma cell line G250 and its use for producing monoclonal antibodies | |
| EP4130043A1 (en) | Anti-human cd47 antibody and antigen-binding fragment thereof, and preparation method therefor and use thereof | |
| Xiang et al. | Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells | |
| CN116063512B (zh) | 多功能重组抗体及其制备方法和应用 | |
| JP2026501279A (ja) | 抗インターロイキン－６抗体の投与による心筋炎の処置 | |
| FI102115B (fi) | Diagnostiikassa käytettävä monoklonaalinen vasta-ainekoostumus ja sitä sisältävä testipakkaus | |
| TW202222836A (zh) | 特異性結合糖基化ceacam5的抗體 | |
| JP2021519589A (ja) | インターロイキン１７ａ（ｉｌ−１７ａ）に結合する抗体を用いた自己免疫障害及び炎症障害の治療 | |
| EP1733736A2 (en) | Method of producing recombinant antibodies against tumours |